Orobika Tablets 5/40 mg
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Jinyang Pharmaceutical Co., Ltd.
MFDS item code 202003043 · Approved 2020.04.24
This product's status changed to Expired on 2025.04.24. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of essential hypertension not controlled with monotherapy
This medication is prescribed for patients with essential hypertension who have difficulty controlling their blood pressure even with either amlodipine or olmesartan medoxomil alone. Essential hypertension refers to a persistent state of high blood pressure, and it is critical to effectively lower it. This medication helps to dilate blood vessels and regulate blood pressure to appropriate levels. Proper blood pressure management can significantly reduce the risk of complications such as heart disease or stroke. Therefore, this medication is used for the treatment of essential hypertension.
Administer 1 tablet once daily with water, regardless of meals. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose of each individual component (amlodipine or olmesartan medoxomil) be adjusted. However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient’s blood pressure response into consideration. The recommended doses are as follows. - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and administration of this medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended for patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine must not be administered to patients with severe hepatic impairment. (Refer to “2. Patients Who Must Not Receive This Medicine” under Precautions for Use.) ∘Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, take the patient’s renal or cardiac function and comorbid diseases into consideration. In elderly patients, blood pressure should be monitored closely and more frequently.
∘Pediatric patients: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it must be discontinued immediately upon confirmation of pregnancy. Individuals who are allergic to any components of this medication or similar drugs, pregnant or breastfeeding women, patients with severe liver or heart diseases, patients with biliary obstruction, patients undergoing dialysis, and patients with certain kidney diseases or diabetes should not take this medication. Patients who are deficient in fluid or salt may experience hypotension, so caution is needed, and patients with sudden vascular dilation or weakened cardiac function should also take it carefully. This medication may cause side effects such as dizziness, headache, hypotension, cough, digestive disturbances, skin rash, muscle pain, and swelling, so any unusual symptoms should be discussed with a doctor. Especially during pregnancy, this medication can have serious effects on the fetus, so those planning to become pregnant or who are pregnant should consult with a doctor. During breastfeeding, this medication may pass into breast milk and affect the baby, so breastfeeding should be discontinued or medication should be stopped. It is not recommended for children under 18, as the safety and efficacy of this medication have not been established. Elderly patients may experience decreased kidney and liver function, so they should start with a low dose and take it with caution. Overdosing on this medication can lead to severe hypotension and cardiac dysfunction, so strict adherence to the prescribed dose is essential, and immediate medical attention is required in case of overdose. Taking this medication with grapefruit juice may excessively enhance the blood pressure-lowering effect, so co-administration should be avoided. Taking it with other antihypertensive medications or potassium-sparing diuretics may increase serum potassium levels, so regular blood tests are necessary. Store this medication out of reach of children, and avoid exposure to moisture, heat, and direct sunlight.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to avoid exposure to air and moisture. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius. Proper storage can help maintain the medication's efficacy for a long time.
Pale yellow round film-coated tablets
30 tablets/box [(10 tablets/PTP X 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Jinyang Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.